Andrade Ana Lucia S S, Martelli Celina M T, Oliveira Renato M, Silva Simonne A, Aires Andréa I S, Soussumi Lea M T, Covas Dimas T, Silva Luiz S, Andrade João G, Travassos Luiz R, Almeida Igor C
Institute of Tropical Pathology and Public Health, Department of Community Health, Federal University of Goias, Rua Delenda R Melo, S/N, Goiânia 74605-050, Brazil.
Am J Trop Med Hyg. 2004 Nov;71(5):594-7.
Data from a six-year follow-up of Trypanosoma cruzi-infected adolescents enrolled in a randomized, double-blind, clinical trial of benznidazole showed successful chemotherapy in 64.7% (95% confidence interval [CI] = 50.2-78.7) and 84.7% (95% CI = 66.8-92.9), respectively, by intention-to treat and by per protocol analysis measured by seronegativity in a chemiluminescent enzyme-linked immunosorbent assay with a purified trypomastigote mucin antigen. No incident case of cardiomyopathy was detected by electrocardiogram assessment in this cohort of adolescents who had been infected in childhood. The persistent and consistently long-term negative serologic reactions suggest the absence of the parasite in the treated patients and reinforces the recommendation of early benznidazole chemotherapy for T. cruzi-infected infants as a public health policy in endemic areas.
对参加苯硝唑随机双盲临床试验的克氏锥虫感染青少年进行的六年随访数据显示，在意向性治疗分析中，化疗成功率为64.7%（95%置信区间[CI]=50.2 - 78.7）；在符合方案分析中，以纯化的锥鞭毛体粘蛋白抗原进行化学发光酶联免疫吸附测定，以血清学阴性为衡量标准，化疗成功率为84.7%（95%CI = 66.8 - 92.9）。在该童年期即受感染的青少年队列中，通过心电图评估未检测到心肌病发病病例。持续且长期的阴性血清学反应表明治疗后的患者体内不存在寄生虫，这强化了在流行地区将对克氏锥虫感染婴儿进行早期苯硝唑化疗作为公共卫生政策的建议。
